Abstract:1685 Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma. Its cure rate has improved over the last two decades in the rituximab era. However, about one-third of patients are refractory/ relapsed ultimately. Early detection of such patients and applying more intensive treatment may help improve prognosis. 18F-FDG PET / CT is widely used in initial staging and post-treatment response assessment, while its value in prognosis is still challenge. The purpose of this study was to explore whether the baseline PET/CT parameters can identify refractory/ relapsed disease in advanced stage patients. Methods: Eighty-three advanced stage untreated DLBCL patients were enrolled in this study, including 43 males and 40 females, with a median age of 60 years. There were 18 cases of Ann Arbor stage III and 65 cases of stage IV. After baseline PET/CT examination, all patients received R-CHOP or R-CHOP-like regimen treatment in our hospital and were followed up for at least 3 years. Refractory/ relapsed disease was defined as progressive or stable disease during treatment, or relapse within 1 year of diagnosis after an initial CR. The tumor VOIs were semi automatically defined on the attenuation-corrected PET images by using a threshold of SUV ≥ 2.5 on local image features extraction (LifeX) software, with segmentation correction performed manually by consensus by two experienced nuclear medicine physicians. SUVmax, metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG) were then calculated. The clinical data including Ann Arbor stage, B symptom, bulky mass, bone marrow involvement, important extranodal involvement, LDH level and NCCN-IPI score were also analyzed. Univariate and multivariate logistic regression analysis was used to identify the independent risk factors for refractory / relapsing patients. PFS and OS were estimated by the Kaplan-Meyer survival analyses, and the difference was compared using a log-rank test. Univariate and multivariate Cox regression models was used to identify the independent risk factors for PFS and OS. Results: There were 44 patients in non- refractory/ relapsed group and 39 patients in refractory/ relapsed group. The MTV and TLG of refractory/ relapsed group was significantly higher than that of non- refractory/ relapsed group (MTV: 1579.9 cm3 Vs. 484.7cm3, P =0.000; TLG: 7853.8 Vs. 3015.8, P =0.000). There was no significant difference of SUVmax between the two groups (15.9 Vs. 17.5, P= 0.248). In the univariate Logistic regression analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, bone marrow involvement, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and TLG were the independent risk factors in prediction refractory/ relapsing disease. In the multivariate Logistic regression analysis, only elevated LDH level and high TLG were the independent risk factors (elevated LDH: HR= 5.233, 95% CI= 1.234-22.183, P=0.025; TLG>2098: HR= 11.914, 95% CI=3.065-46.314, P=0.000). In the univariate Cox analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, bone marrow involvement, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and high TLG were the independent risk factors for PFS. In multivariate Cox analysis, only high TLG was the independent risk factors (HR= 3.049, 95%CI: 1.250-7.438, P=0.014). As to the OS, in the univariate Cox analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and high TLG were the independent risk factors. In multivariate analysis, only B symptom and elevated LDH were the independent risk factors (B symptom: HR= 3.494, 95%CI: 1.489-8.197, P=0.004; elevated LDH: HR= 9.805, 95% CI:1.320-72.831, P=0.026). Conclusions: High MTV and TLG in baseline PET/CT can predict the refractory/relapse disease in patients with advanced DLBCL, and can be used as important prognostic factors.

FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer

Internal dosimetry and biodistribution of indigenously prepared 177Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab

Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients

The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE

Assessing Krenning's score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy

Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography

Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial

Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy

Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

Safety and dosimetry evaluation of radioimmunotherapy using 177Lu-labeled antibodies in lymphoma

A Clinical Study of Baseline PET/CT Parameters in the Prediction of Refractory/relapsed Diffuse Large B Cell Lymphoma of Advanced Stage Patients

Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy